Drugs / 18F-DOPA
18F-DOPA
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | US (FDA) | FLUORODOPA F18 | — | 2019-10-10 | fda.gov ↗ |
Trials 19 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03581305 Comparator | Nov 2018 → Apr 2022 | AIDS dementia complex, HIV infectious disease, depressive disorder | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05781321 Background | Mar 2023 → Jul 2026 overdue | glioblastoma | Mayo Clinic | Active not recruiting | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-DOPA | “Fortunately, \[18F\]-DOPA PET has been shown to be a useful noninvasive imaging method for distinguishing between focal and diffuse forms of hyperinsulinemic hypoglycemia.” NCT02533219 ↗8“6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET)” NCT05088798 ↗ “1 time injection of 0.08 - 0.16 mCi/kg of 18F-DOPA” NCT01468454 ↗ |
| Known as | 18-Fluoro-DOPA | “For diagnostic failure, selective utilization of 18-Fluoro-DOPA PET/CT scanning, arterial stimulation/venous sampling, or transhepatic portal venous sampling were successful in...” PMID 24314196 ↗ Dec 2013 |
| Known as | 18-labeled L-fluorodeoxyphenylalanine | “radioactive drug, 18-labeled L-fluorodeoxyphenylalanine (called F-DOPA)” NCT01468454 ↗ |
| Known as | 18F-FDOPA | “One hour later all patient will be injected intravenously with 185 MBq (5mCi) 18F-FDOPA.” NCT03973502 ↗ |
| Known as | 18F-Fluoro Dopa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05088798 ↗ |
| Known as | 18F-fluoro-dihydroxyphenylalanine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02175745 ↗ |
| Known as | 6-[18F]-Fluoro-L-3,4,-dihydroxyphenylalanine | “6-\[18F\]-Fluoro-L-3,4,-dihydroxyphenylalanine (18F-DOPA)positron emission tomography (PET)” NCT05088798 ↗ |
| Known as | 6-[18F]fluorolevodopa (U.S. Pharmacopeia) | “6-[18F]fluorolevodopa (U.S. Pharmacopeia)” NCT02021604 ↗ |
| Known as | F-DOPA | “radioactive drug, 18-labeled L-fluorodeoxyphenylalanine (called F-DOPA)” NCT01468454 ↗ |
| Known as | Fluorine F 18 Fluorodopa | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03242824 ↗ |
| Known as | Fluorodopa 18F (International Non-Proprietary Name) | “Fluorodopa 18F (International Non-Proprietary Name)” NCT02021604 ↗ |
| Known as | Fluorodopa F 18 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05781321 ↗ |
| Known as | Fluorodopa F 18 (CAS Number 75290-51-6) | “Fluorodopa F 18 (CAS Number 75290-51-6)” NCT02021604 ↗ |
| Modality | Diagnostic / imaging agent | “Patients scanned using imaging agents 68GALLIUM-DOTATATE and 18F-DOPA” NCT00001277 ↗ |
| Route | Intravenous | “Given IV” NCT01165632 ↗ |